Repligen Completes Acquisition of BioLife Solutions
Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.
How this was made
The 30-second read
Why it matters
The completion of the deal provides Repligen with a high‑margin consumables business and recurring revenue, while BioLife shareholders receive cash and Repligen stock, ending BioLife's independent public listing.
Market read
The acquisition is a material M&A event for both companies, likely influencing Repligen's valuation and removing BioLife from the market.
What to watch
Potential regulatory scrutiny of the combined product portfolio and the impact of the stock‑based consideration on existing shareholders.
Background
Repligen (NASDAQ:RGEN) is a bioprocessing technology company; BioLife (NASDAQ:BLFS) supplies cell‑processing tools for gene‑therapy manufacturers.
Ticker impact
Repligen announced completion of its acquisition of BioLife, issuing cash and stock to BioLife shareholders.
likely upward pressure as the market prices in the strategic benefit and cash component of the transaction
Acquisition adds high‑margin consumables and expands addressable market; cash payment and stock issuance are modest relative to Repligen's market cap.
BioLife shareholders received cash and Repligen stock as consideration for the completed acquisition.
no further price movement; the stock will be delisted after the cash/stock distribution
The transaction fully absorbs BioLife; its equity will be removed from public markets.
Market effects
Strengthens the cell‑therapy bioprocessing niche, potentially boosting peers in the life‑sciences consumables space.
Adds to U.S. biotech M&A activity; modest effect on broader market.
Highlights growing demand for cell‑therapy tools worldwide, especially in Asia‑Pacific.
Counterpoint
If integration costs exceed expectations, the acquisition could dilute earnings and pressure RGEN.
Key entities
- CompanyRepligen Corporation
Acquirer, life‑sciences bioprocessing firm.
- CompanyBioLife Solutions, Inc.
Target, cell‑processing tools provider.
